AbbVie's Q4 earnings report revealed that the company exceeded expectations for both profit and revenue.

AbbVie's Q4 earnings and sales forecast exceeded analyst estimates by $0.02, with adjusted earnings per share of $2.79 and revenue of $14.3 billion.

Adjusted earnings per share declined by 22.5% compared to the previous year, partially due to an adverse impact of $0.15 per share resulting from acquired IPR&D and milestones. 

AbbVie's Q4 sales decreased by 5.4% due to a 40.8% decrease in global Humira revenues and a 7.4% decrease in oncology portfolio revenues.

AbbVie predicts Q4 earnings per share for 2024 to be between $11.05 and $11.25, slightly below the consensus estimate of $11.24.

Truist analysts reaffirmed ABBV's buy rating and $180 price target, while AbbVie increased its 2027 Skyrizi and Rinvoq Q4 earnings and sales forecast to $27 billion.

AbbVie's Q4 earnings and sales forecast predicts an adjusted profit of $11.05 to $11.25 per share for 2024.

AbbVie's earnings and sales forecast for the fourth quarter showed slight growth during the unpredictable premarket trading session.